Biosign Technologies Inc.

Biosign Receives Reimbursement Approval from NexgenRx

    Toronto, March 17, 2010 (ots/PRNewswire) - Biosign Technologies Inc. (CNSX: BIO) (the "Company" or "Biosign") today  announced it has received notification that NexgenRx  will  include Biosign's UFIT(R) device and services into their Benefits Plans for  reimbursement according to regulatory clearances in the relevant  jurisdiction.

    Ronald C. Louks, President & CEO of NexgenRx, said: "We see diabetic  plan members and their dependents migrating to this technology very quickly  as they lessen their dependency on the current invasive monitoring devices.  That alone is reason enough. However, when you factor in the fractionally  lower cost associated with the Biosign monthly monitoring charges, compared  to the cost of the consumable strips that plan sponsors are reimbursing  through health plans, this becomes even more compelling."

    UFIT is Biosign's system for online delivery of health monitoring services to individuals. All services, including blood pressure and blood glucose testing, rely on digital representations of the pulse taken at  the wrist through an inflatable cuff by a portable device connected to a  computer. The noninvasive, multifunctional monitor brings an unprecedented  blend of convenience and performance to self-testing in terms of quality,  access, and cost.

    John Anders SVP, Business Development at Biosign, stated: "The market strength of NexgenRx is derived from combining industry leading technology  and clinical expertise to deliver better medical outcomes at lower costs.  We are very pleased to see that NexgenRx is supportive of our offering as  it fits perfectly into their customer value proposition."

    About Biosign Technologies Inc.  

    Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, medication. The core technology  combines measurement, analysis, and rapid knowledge formation to support  health monitoring across global markets. The UFIT(R) medical device  technology powers quality data collection and analytics for clinical  diagnostics, self-care, wellness, disease state evaluation & management,  and  remote patient monitoring. For more information on Biosign please  visit http://www.biosign.com.

    About NexgenRx  

    NexgenRx is a growing health benefits management company engaged in  the design, management and administration of health benefit plans offered  by employers and other plan sponsors for the benefit of their employees  and plan members. More information on NexgenRx can be found  at http://www.nexgenrx.com.

    The CNSX has neither approved nor disapproved the contents of this  press release.

    For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: +1(416)218-9800 ext. 234,  Email: ceo@biosign.com.

ots Originaltext: Biosign Technologies Inc.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
CONTACT:  For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., Phone: +1(416)218-9800 ext. 234, Email:
ceo@biosign.com.



Weitere Meldungen: Biosign Technologies Inc.

Das könnte Sie auch interessieren: